Archives: 2020-12-18

PIER MARIA FORNASARI
2020-12-18

By October 2020 COVID-19 had become the third leading cause of death in US for persons aged 45 through 84 years and the second for those aged 85 years or older.

Adults 45 years or older were more likely to die from COVID-19 during those months than from chronic lower respiratory disease, transport accidents (eg, motor vehicle fatalities), drug overdoses, suicide, or homicide. In contrast, for individuals younger than age 45 years, other causes of death, such as drug overdoses, suicide, transport accidents, cancer, and homicide

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-12-16

Teaching youngsters about the magnificent world of Advanced Therapies. RESTORE Consortium experiences a new formation/information tool for disseminating CAR-T Cells Therapy in Haematologic diseases.

“Thanks to this technology and to the specific fighting capabilities of these cells, extraordinary results have been obtained: The therapy is a new hope for patients who no longer responded to other treatments. The therapy seems to have a long-lasting effect after a single application Unlike many other therapies, which benefit only a small portion

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-12-15

Research Could Offer Novel Way to Restore Lung Function to COVID-19 Patients

Targeting endothelial cells –cells that comprise the blood vessel wall which regulate oxygen exchange between airways and the bloodstream– may be a novel approach restoring normal lung function to Covid-19 patients with serious lung disease. This hypothesis stems from a study by researchers in the Department of Microbiology and Immunology in the Renaissance School of

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-12-14

Data Monitoring Committee of Pluristem Phase III Critical Limb Ischemia says primary endpoint has not been reached

The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpoint PLX-PAD was well tolerated, and no safety concerns were raised Company to terminate the CLI study to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar year

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-12-12

New Online COVID-19 Mortality Risk Calculator Could Help Determine Who Should Get Vaccines First

CALCULATOR GENERATES MORTALITY RISK ESTIMATES FOR INDIVIDUALS AND COMMUNITIES BASED ON SOCIODEMOGRAPHIC INFO AND MEDICAL HISTORY A new online calculator for estimating individual and community-level risk of dying from COVID-19 has been developed by researchers at the Johns Hopkins Bloomberg School of Public Health. The researchers who developed the calculator expect it to be useful to

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-12-11

Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic

During the coronavirus disease 2019 (COVID-19) pandemic, the general public has been advised to wear masks or improvised face coverings to limit transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there has been considerable confusion and disagreement regarding the degree to which masks protect thewearer from airborne particles. To evaluate the fitted filtration

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-12-11

Repurposed Antiviral Drugs for Covid-19 —Interim WHO Solidarity Trial Results confirmed none of tested drugs reduced mortality

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir and interferon beta-1a) in patients hospitalized with Covid-19. Inpatients with Covid-19 were randomly assigned equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-12-11

FDA Vaccines and Related Biological Products Advisory Committee Recommends COVID-19 Vaccine For Emergency Use

In a 17-4 vote, with one abstention, a panel of advisers to the Food and Drug Administration recommended Thursday that the COVID-19 vaccine being developed by Pfizer and BioNTech be authorized for emergency use during the coronavirus pandemic. The vote in favor of the vaccine was taken to answer the agency’s question: Do the benefits

Read More

No Comments InCovid-19